Patent ID: 9688769
Date: 2017-06-27
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method of alleviating a symptom of a disorder associated with excessive aberrant TLR4 signaling or elevated TLR4 ligand expression or activity, wherein the disorder is an autoimmune or inflammatory disorder, the method comprising: (a) detecting a level of one or more TLR4 ligands or one or more other biomarkers selected from the group consisting of anti-citrullinated protein antibody (ACPA), a citrullinated fibrinogen (cFb) in an immune complex with an IgG protein (cFb-IC), HMGB1, S100A8/A9, Tenascin C, and combinations thereof in a biological sample from a subject, (b) comparing the detected level of the one or more TLR4 ligands or the one or more biomarkers to a control level of expression selected from the group consisting of: (c) identifying the subject as a responder when the detected level of the one or more TLR4 ligands or one or more other biomarkers is greater than the control level of expression, or identifying the subject as a non-responder when the detected level of expression of the one or more TLR4 ligands or one or more other biomarkers is lower than the control level of expression, and (d) administering an anti-TLR4 antibody or immunologically active fragment thereof in an amount sufficient to alleviate the symptom of the disorder when the subject is identified as a responder.